Track topics on Twitter Track topics that are important to you
Colorectal Cancer Therapeutics in AsiaPacific Markets to 2023 Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
Colorectal Cancer CRC is the most common cancer and the leading cause of cancerrelated mortality globally. There were more than 1.4 million newly diagnosed CRC cases in 2012, accounting for 9.7% of the total number of cancer cases. This figure has been gradually rising in the AsiaPacific region, with the growing elderly population and increasingly Westernized lifestyles.
CRC is a leading cause of death worldwide, accounting for 0.77 million deaths in 2015. Over half of the incident cases of CRC are diagnosed in patients over the age of 50, and as the aged population is projected to grow, the prevalence of CRC is anticipated to increase, acting as a driver for revenue growth.
The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The CRC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations.
The marketed products landscape comprises a wide range of treatment options, including EGFRtargeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies. In the current market, RASwildtype and RASmutant patients can be treated with angiogenesis inhibitors such as Avastin, Cyramza and Zaltrap, while patients with RAS or KRASwildtype mutations can be prescribed EGFRtargeted therapies such as Erbitux and Vectibix. However, significant unmet need remains for products that can treat BRAFmutant CRC patients. A therapy that targets mutant BRAF encorafenib plus binimetinib is being developed in the pipeline.
The CRC AsiaPacific market will be valued at $7.9 billion in 2023, growing from $4.7 billion in 2016 at a CAGR of 7.9%.
How will immune checkpoint inhibitors such as Keytruda and Tecentriq contribute to growth?
What effect will patent expirations of currently branded therapies have on market value?
The CRC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies.
What are the common targets and mechanisms of action of pipeline therapies?
Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAFmutant CRC patients?
What implications will the increased focus on targeted therapies have on the future of CRC treatment?
Numerous latestage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
How have the latestage therapies performed in clinical trials?
How would the approval of encorafenib plus binimetinib to treat BRAFmutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
The market forecasts indicate that Japan will contribute the most to the AsiaPacific market value due to the emergence of novel therapies.
How will the annual cost of therapy and market size vary between the five assessed AsiaPacific markets?
How could changes in risk factors such as population age, obesity and lifestyle influence the market?
Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $3 billion.
How do deal frequency and value compare between target families and molecule types?
What were the terms and conditions of key licensing deals?
Reasons to buy
Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
Understand the potential of latestage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
Predict CRC market growth in the five assessed AsiaPacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising latestage molecules to market growth.
Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and codevelopment deals.
Original Article: Colorectal Cancer Therapeutics in AsiaPacific Markets to 2023 Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market [Report Updated: 01072017] Prices from USD $4995NEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...